Ranbaxy spinout gets $6.5M for N.J.-based generics biz
Bionpharma just raised $6.5 million, according to a regulatory filing - on top of about $31 million raised last year.
Bionpharma just raised $6.5 million, according to a regulatory filing - on top of about $31 million raised last year.
Ranbaxy‘s generic pharmaceuticals business in the U.S. has been suspended until it can correct violations at its factories in India and the United States that triggered a federal injunction. Under the terms of a settlement reached with the U.S. Department of Justice, which described its investigation of the company as “groundbreaking,” the company is to […]
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.